Atea Pharmaceuticals (AVIR) Free Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$46.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 51.79% year-over-year to -$46.4 million in Q1 2026; TTM through Mar 2026 was -$147.9 million, a 17.17% decrease from a year earlier, with the FY2025 full-year figure at -$132.0 million, up 2.56% from the prior year.
• Free Cash Flow retreated to -$46.4 million in Q1 2026 per AVIR's latest filing, from -$28.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$16.1 million in Q2 2023 and bottomed at -$59.1 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$29.8 million (2023), against an average of -$30.7 million.
• Biggest YoY gain for Free Cash Flow was 71.43% in 2022; the steepest drop was 250.73% in 2022.
• Year by year, Free Cash Flow stood at -$21.5 million in 2022, then fell by 1.34% to -$21.8 million in 2023, then plunged by 39.22% to -$30.4 million in 2024, then advanced by 7.15% to -$28.2 million in 2025, then sank by 64.37% to -$46.4 million in 2026.
• Per Business Quant, the three latest AVIR Free Cash Flow figures stand at -$46.4 million (Q1 2026), -$28.2 million (Q4 2025), and -$40.4 million (Q3 2025).